| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 04/10/2003 | US20030069308 Antidiabetic agents |
| 04/10/2003 | US20030069297 4-aryl substituted indolinones |
| 04/10/2003 | US20030069294 Alpha-substituted carboxylic acid derivatives |
| 04/10/2003 | US20030069292 Central nervous system disorders; anticonvulsants |
| 04/10/2003 | US20030069288 Substituted aminomethyl-phenyl-cyclohexane derivatives |
| 04/10/2003 | US20030069287 Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors |
| 04/10/2003 | US20030069274 Pharmaceutically active compounds and methods of use |
| 04/10/2003 | US20030069260 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors |
| 04/10/2003 | US20030069249 Analgesics; central nervous system disorders |
| 04/10/2003 | US20030069248 Antiinflammatory agents; controlling cell cycle |
| 04/10/2003 | US20030069246 Central nervous system disorders; psychological disorders; cardiovascular disorders |
| 04/10/2003 | US20030069243 Novel substituted imidazole compounds |
| 04/10/2003 | US20030069241 Analgesics; central nervous system disorders; gastrointestinal disorder; therapy for drug abruse ; antiinflammatory agents |
| 04/10/2003 | US20030069238 Anticancer agents; immunology diseases; antiallergens; antiinflammatory agents |
| 04/10/2003 | US20030069228 Capase inhibitors; antiinflammatory agents |
| 04/10/2003 | US20030069221 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 04/10/2003 | US20030069217 Methods of prevention and treatment of ischemic damage |
| 04/10/2003 | US20030069210 Especially imidazolyl- or 1,2,4-triazolyl- pyrimidine derivatives |
| 04/10/2003 | US20030069202 Compositions, kits, and methods for promoting defined health benefits |
| 04/10/2003 | US20030069189 Administering an NF-kappa B activation inhibitor that is a proteasome inhibitor, ubiquitin pathway inhibitor, agent that interferes with activation of NF-kappa B via the ubiquitin proteasome pathway |
| 04/10/2003 | US20030069186 Chimeric natriuretic peptides |
| 04/10/2003 | US20030069181 Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| 04/10/2003 | US20030069169 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders |
| 04/10/2003 | US20030068387 Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders |
| 04/10/2003 | US20030068366 Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
| 04/10/2003 | CA2462795A1 Secreted proteins |
| 04/10/2003 | CA2462643A1 Triazepine derivatives as neurotrophic agents |
| 04/10/2003 | CA2462601A1 Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
| 04/10/2003 | CA2462443A1 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease |
| 04/10/2003 | CA2462419A1 N-heterocyclyl hydrazides as neurotrophic agents |
| 04/10/2003 | CA2462305A1 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade |
| 04/10/2003 | CA2462275A1 Novel composition of carvedilol |
| 04/10/2003 | CA2462142A1 Benzisothiazolyl-substituted aminomethyl chromanes for treating diseases of the central nervous system |
| 04/10/2003 | CA2462112A1 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 04/10/2003 | CA2462030A1 3-`hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7,8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors |
| 04/10/2003 | CA2461919A1 Substituted 2,5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases |
| 04/10/2003 | CA2461686A1 Preparation of an anhydrous quinoline-based cetp inhibitor by crystallization |
| 04/10/2003 | CA2461099A1 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof |
| 04/10/2003 | CA2460917A1 Human tissue factor antibodies |
| 04/10/2003 | CA2460486A1 Pseudopolymorphic forms of carvedilol |
| 04/10/2003 | CA2460257A1 Methods for diagnosing and treating heart disease |
| 04/10/2003 | CA2459825A1 Compounds useful as reversible inhibitors of cysteine proteases |
| 04/10/2003 | CA2458343A1 Pharmaceutical combinations of pde-v inhibitors and other agents |
| 04/10/2003 | CA2455225A1 Novel proteins and nucleic acids encoding same |
| 04/10/2003 | CA2453343A1 Tetracyclic indole derivatives as 5-ht receptor ligands |
| 04/10/2003 | CA2430328A1 Receptor antagonist |
| 04/09/2003 | EP1300424A1 Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use |
| 04/09/2003 | EP1300399A1 Phenylpyridazine derivatives and drugs containing the same |
| 04/09/2003 | EP1300396A1 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
| 04/09/2003 | EP1300166A1 Means for treatment of coronary artery obstructions |
| 04/09/2003 | EP1300158A1 Medicinal compositions for angiogenic therapy |
| 04/09/2003 | EP1300148A2 Use of bismuth subgallate in inhibition of production of nitric oxide synthase |
| 04/09/2003 | EP1300084A2 Composition for the treatment of chronic venous insufficiencies comprising an extract of red vine leaves |
| 04/09/2003 | EP1299548A1 Novel therapeutic molecular variants and uses thereof |
| 04/09/2003 | EP1299545A2 Drug metabolizing enzymes |
| 04/09/2003 | EP1299538A2 Secreted proteins |
| 04/09/2003 | EP1299536A1 Novel alpha-catenin expressed in heart and testis |
| 04/09/2003 | EP1299534A2 Grf2-binding proteins and applications thereof |
| 04/09/2003 | EP1299424A1 COLD WATER SOLUBLE $g(b)-GLUCAN PRODUCT AND PROCESS FOR PREPARING THE SAME |
| 04/09/2003 | EP1299421A2 Antibodies to human mcp-1 |
| 04/09/2003 | EP1299419A2 Bispecific immunoglobulin-like antigen binding proteins and method of production |
| 04/09/2003 | EP1299415A1 Chemokine receptor modulators, production and use |
| 04/09/2003 | EP1299412A2 Protein modification and maintenance molecules |
| 04/09/2003 | EP1299410A2 GFR alpha1-RET SPECIFIC AGONISTS AND METHODS THEREFOR |
| 04/09/2003 | EP1299385A2 Fused cyclic modulators of nuclear hormone receptor function |
| 04/09/2003 | EP1299383A1 Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders |
| 04/09/2003 | EP1299378A1 Tetrahydropyridino or piperidino heterocyclic derivatives |
| 04/09/2003 | EP1299374A1 Novel non-psychotropic cannabinoids |
| 04/09/2003 | EP1299365A1 2-aminothiazoline derivatives and their use as no-synthase inhibitors |
| 04/09/2003 | EP1299363A1 Polymorphic forms/hydrates of n- 4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride |
| 04/09/2003 | EP1299362A1 Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof |
| 04/09/2003 | EP1299358A2 Pyridoxine and pyridoxal analogues: cardiovascular therapeutics |
| 04/09/2003 | EP1299355A2 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors |
| 04/09/2003 | EP1299352A2 Compounds to treat alzheimer's disease |
| 04/09/2003 | EP1299351A1 Novel aryl, alkenyl, and alkynl 4-dedimethylaminotetracycline derivatives |
| 04/09/2003 | EP1299349A2 Compounds to treat alzheimer's disease |
| 04/09/2003 | EP1299125A1 Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| 04/09/2003 | EP1299121A2 Thromboxane receptor antagonist containing formulations for potentiating organic nitrates having vasodilating activity |
| 04/09/2003 | EP1299103A1 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors |
| 04/09/2003 | EP1299101A1 Carvedilol |
| 04/09/2003 | EP1299096A1 Prostaglandin compounds for treating congestive heart failure |
| 04/09/2003 | EP1299092A2 Use of fluorescein derivatives for the treatment of diseases responsive to the activation of the cystic fibrosis transmembrane conductance regulator chloride channel |
| 04/09/2003 | EP1299091A2 Matrix controlled transdermal system for stabile derivatives of ace inhibitors |
| 04/09/2003 | EP1299089A2 Drug delivery system for poorly water soluble drugs |
| 04/09/2003 | EP1299010A1 Vitamin k and essential fatty acids |
| 04/09/2003 | EP1230342A4 Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
| 04/09/2003 | EP1220844B1 Aryl sulfonamide-substituted benzimidazol derivatives thereof as tryptase inhibitors |
| 04/09/2003 | EP1133473B1 New manufacturing process |
| 04/09/2003 | EP1109567A4 Drug screening and diagnosis based on paracrine tubular renin-angiotensin system |
| 04/09/2003 | EP1001766B1 Compounds for the treatment of ccr5-mediated diseases |
| 04/09/2003 | EP0996612B1 Aliphatic propargylamines as cellular rescue agents |
| 04/09/2003 | EP0993458B1 3-benzylpiperidine |
| 04/09/2003 | EP0986580B1 Oligosaccharide mixtures having antithrombotic activity |
| 04/09/2003 | EP0946528B1 OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS |
| 04/09/2003 | EP0946165B1 Integrin antagonists |
| 04/09/2003 | EP0906303B1 Ring-fused dihydropyranes, process for the preparation and use thereof |
| 04/09/2003 | EP0892793B1 Substituted tetracyclic tetrahydrofuran derivatives |
| 04/09/2003 | EP0873123B1 Inhibitors of protein isoprenyl transferases |
| 04/09/2003 | EP0842156B1 Novel n-(2,4-dioxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3yl)-3-amides |
| 04/09/2003 | EP0793492B1 Use of sclareolide for treating disorders characterised by excessive cell proliferation |